CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB4455 : PC-9]

17817 Ohkawa Y, Kitano M, Maeda K, Nakano M, Kanto N, Kizuka Y, Seike M, Azuma A, Yamaguchi Y, Ookawara T, Miyoshi E, Taniguchi N. Core Fucosylation Is Required for the Secretion of and the Enzymatic Activity of SOD3 in Nonsmall-Cell Lung Cancer Cells Antioxid Redox Signal 2023 Mar 6 PubMed ID: 36606688 DOI: 10.1089/ars.2022.0010

20946 Takumi Y, Arai S, Suzuki C, Fukuda K, Nishiyama A, Takeuchi S, Sato H, Matsumoto K, Sugio K, Yano S. MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements. Cancer Med 2023 12(5):5809-5820 PubMed ID: 36416133 DOI: 10.1002/cam4.5342

21119 Tokumo K, Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Okada M, Hamada H, Hattori N. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition. Cancers (Basel) 2023 15(4) PubMed ID: 36831438 DOI: 10.3390/cancers15041092

21131 Konishi H, Haga Y, Lin Y, Tsujino H, Higashisaka K, Tsutsumi Y. Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis. Biochem Biophys Res Commun 2023 641:116-122 PubMed ID: 36527745 DOI: 10.1016/j.bbrc.2022.12.029

21136 Sumimoto H, Takano A, Igarashi T, Hanaoka J, Teramoto K, Daigo Y. Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. Sci Rep 2023 13(1):5087 PubMed ID: 36991099 DOI: 10.1038/s41598-023-32177-4

21224 Kim M, Kim S, Yim J, Keam B, Kim TM, Jeon YK, Kim DW, Heo DS. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Cancer Res Treat 2023 PubMed ID: 37218137 DOI: 10.4143/crt.2023.311

17574 Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells Cancer Sci 2022 113(7):2323-2335 PubMed ID: 35363931 DOI: 10.1111/cas.15354

20516 Fan D, Yang Y, Zhang W. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells. BMC Pulm Med 2022 22(1):27 PubMed ID: 34996416 DOI: 10.1186/s12890-021-01731-z

20523 Gebreyesus ST, Siyal AA, Kitata RB, Chen ES, Enkhbayar B, Angata T, Lin KI, Chen YJ, Tu HL. Streamlined single-cell proteomics by an integrated microfluidic chip and data-independent acquisition mass spectrometry. Nat Commun 2022 13(1):37 PubMed ID: 35013269 DOI: 10.1038/s41467-021-27778-4

20529 Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells. Cancer Med 2022 11(4):944-955 PubMed ID: 35029047 DOI: 10.1002/cam4.4504

20595 Matsushige T, Sakabe T, Umekita Y. Investigation of the Subcellular Localization-Dependent Anti- or Pro-Tumor Functions of Maspin in Human Lung Adenocarcinoma Cell Line. Yonago Acta Med 2022 65(1):44-52 PubMed ID: 35221759 DOI: 10.33160/yam.2022.02.006

16503 Tsuchiya K, Yoshimura K, Iwashita Y, Inoue Y, Ohta T, Watanabe H, Yamada H, Kawase A, Tanahashi M, Ogawa H, Funai K, Shinmura K, Suda T, Sugimura H. m 6 A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer Cancer Gene Ther 2022 Mar 22 PubMed ID: 35318440 DOI: 10.1038/s41417-022-00451-8

16726 Grinkevitch V, Wappett M, Crawford N, Price S, Lees A, McCann C, McAllister K, Prehn J, Young J, Bateson J, Gallagher L, Michaut M, Iyer V, Chatzipli A, Barthorpe S, Ciznadija D, Sloma I, Wesa A, Tice DA, Wessels L, Garnett M, Longley DB, McDermott U, McDade SS. Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists Mol Cancer Ther 2022 21(4):594-606 PubMed ID: 35086954 DOI: 10.1158/1535-7163.MCT-21-0532

16854 Masaki Takahashi, Yoshifumi Hashimoto, Yoshikazu Nakamura Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model Molecular Therapy - Nucleic Acids 2022 29:969-978 PubMed ID: 36189081 DOI: 10.1016/j.omtn.2022.06.001

20821 Li C, Zheng H, Xiong J, Huang Y, Li H, Jin H, Ai S, Wang Y, Su T, Sun G, Xiao X, Fu T, Wang Y, Gao X, Liang P. miR-596-3p suppresses brain metastasis of non-small cell lung cancer by modulating YAP1 and IL-8. Cell Death Dis 2022 13(8):699 PubMed ID: 35961957 DOI: 10.1038/s41419-022-05062-7

20848 Satoh K, Sakai S, Nishizuka M. Knockdown of RhoQ, a member of Rho GTPase, accelerates TGF-β-induced EMT in human lung adenocarcinoma. Biochem Biophys Rep 2022 32:101346 PubMed ID: 36120491 DOI: 10.1016/j.bbrep.2022.101346

20859 Onishi T, Takashima T, Kurashige M, Ohshima K, Morii E. Mutually exclusive expression of EZH2 and H3K27me3 in non-small cell lung carcinoma. Pathol Res Pract 2022 238:154071 PubMed ID: 35985089 DOI: 10.1016/j.prp.2022.154071

20935 Deng H, Lei Q, Wang C, Wang Z, Chen H, Wang G, Yang N, Huang D, Yu Q, Yao M, Xiao X, Zhu G, Cheng C, Li Y, Li F, Tian P, Li W. A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. Nat Commun 2022 13(1):6944 PubMed ID: 36376325 DOI: 10.1038/s41467-022-34627-5

20104 Abe K, Kanehira M, Ohkouchi S, Kumata S, Suzuki Y, Oishi H, Noda M, Sakurada A, Miyauchi E, Fujiwara T, Harigae H, Okada Y. Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer. Cancer Med 2021 PubMed ID: 33826244 DOI: 10.1002/cam4.3852

14291 Isomura H, Taguchi A, Kajino T, Asai N, Nakatochi M, Kato S, Suzuki K, Yanagisawa K, Suzuki M, Fujishita T, Yamaguchi T, Takahashi M, Takahashi T. Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator Cancer Sci 2021 112(4):1614-1623 PubMed ID: 33506575 DOI: 10.1111/cas.14825

14368 Khaledian B, Taguchi A, Shin-Ya K, Kondo-Ida L, Kagaya N, Suzuki M, Kajino T, Yamaguchi T, Shimada Y, Takahashi T. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma Cancer Sci 2021 112(3):1225-1234 PubMed ID: 33370472 DOI: 10.1111/cas.14786

20304 Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K. Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients. Lung Cancer 2021 158:115-125 PubMed ID: 34157583 DOI: 10.1016/j.lungcan.2021.06.011

20365 He W, Qin M, Cai Y, Gao X, Cao S, Wang Z, Chen H, Xu R. Downregulation of HOXC6 by miR-27a ameliorates gefitinib resistance in non-small cell lung cancer. Am J Cancer Res 2021 11(9):4329-4346 PubMed ID: 34659890

15836 Nanamiya R, Saito-Koyama R, Miki Y, Inoue C, Asavasupreechar T, Abe J, Sato I, Sasano H. EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer Int J Mol Sci 2021 22(16):8522 PubMed ID: 34445227 DOI: 10.3390/ijms22168522

15839 Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. dentification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer Nat Commun 2021 12(1):3697 PubMed ID: 34140482 DOI: 10.1038/s41467-021-23912-4

15840 Fukuda K, Otani S, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K, Yano S. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer Cancer Sci 2021 112(9):3784-3795 PubMed ID: 34145930 DOI: 10.1111/cas.15035

15846 Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma Cancer Med 2021 10(2):718-727 PubMed ID: 33305905 DOI: 10.1002/cam4.3639

15883 Xue L, Gao X, Zhang H, Tang J, Wang Q, Li F, Li X, Yu X, Lu Z, Huang Y, Tang R, Yang W. Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment BMC Cancer 2021 21(1):1134 PubMed ID: 34686154 DOI: 10.1186/s12885-021-08859-5

16219 Jeongmin Hong, Aya Shiba‐Ishii, Yunjung Kim, Masayuki Noguchi, Noriaki Sakamoto Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma Cancer Sci 2021 112(12):5114-5126 PubMed ID: 34628698 DOI: 10.1111/cas.15160

16281 Nachankar A, Oike T, Hanaoka H, Kanai A, Sato H, Yoshida Y, Obinata H, Sakai M, Osu N, Hirota Y, Takahashi A, Shibata A, Ohno T. 64 Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity Cancers (Basel) 2021 13(24):6159 PubMed ID: 34944777 DOI: 10.3390/cancers13246159

20624 Nozaki M, Nishizuka M. Repression of RhoJ expression promotes TGF-β-mediated EMT in human non-small-cell lung cancer A549cells. Biochem Biophys Res Commun 2021 566:94-100 PubMed ID: 34119829 DOI: 10.1016/j.bbrc.2021.06.004

16516 Tsuchiya K, Yoshimura K, Inoue Y, Iwashita Y, Yamada H, Kawase A, Watanabe T, Tanahashi M, Ogawa H, Funai K, Shinmura K, Suda T, Sugimura H. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer Oncoimmunology 2021 10(1):1962656 PubMed ID: 34408926 DOI: 10.1080/2162402X.2021.1962656

18105 Liu J, Han X, Chen L, Han D, Mu X, Hu X, Wu H, Wu H, Liu W, Zhao Y. TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma Aging (Albany NY) 2020 12(20):20308-20331 PubMed ID: 33091876 DOI: 10.18632/aging.103804

7054 Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. J Thorac Oncol 2020 15(5):752-765 PubMed ID: 31972351 DOI: 10.1016/j.jtho.2020.01.001

11955 Ren T, Fan XX, Wang MF, Duan FG, Wei CL, Li RZ, Jiang ZB, Wang YW, Yao XJ, Chen MW, Tang YJ, Leung EL. miR‑20b promotes growth of non‑small cell lung cancer through a positive feedback loop of the Wnt/β‑catenin signaling pathway. Int. J. Oncol. 2020 PubMed ID: 31894264 DOI: 10.3892/ijo.2019.4940

12050 Azuma Y, Yokobori T, Mogi A, Yajima T, Kosaka T, Iijima M, Shimizu K, Shirabe K, Kuwano H. Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells. Surg. Today 2020 PubMed ID: 32052182 DOI: 10.1007/s00595-020-01976-x

12085 Lin Y, Higashisaka K, Shintani T, Maki A, Hanamuro S, Haga Y, Maeda S, Tsujino H, Nagano K, Fujio Y, Tsutsumi Y. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells. Sci Rep 2020 PubMed ID: 32179851 DOI: 10.1038/s41598-020-61727-3

12089 Tanaka H, Hino H, Moriya S, Kazama H, Miyazaki M, Takano N, Hiramoto M, Tsukahara K, Miyazawa K. Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin. Biochem Biophys Rep 2020 PubMed ID: 32195376 DOI: 10.1016/j.bbrep.2020.100750

13153 Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C. Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing. Biomedicines 2020 PubMed ID: 32764319 DOI: 10.3390/biomedicines8080273

13224 Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat Commun 2020 PubMed ID: 32929081 DOI: 10.1038/s41467-020-18442-4

13283 Arai S, Takeuchi S, Fukuda K, Tanimoto A, Nishiyama A, Konishi H, Takagi A, Takahashi H, Ong ST, Yano S. Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. J Med Invest 2020 PubMed ID: 33148913 DOI: 10.2152/jmi.67.343

13543 Okuno D, Sugiura Y, Sakamoto N, Tagod MSO, Iwasaki M, Noda S, Tamura A, Senju H, Umeyama Y, Yamaguchi H, Suematsu M, Morita CT, Tanaka Y, Mukae H. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells Front Immunol 2020 11:1405 PubMed ID: 32793196 DOI: 10.3389/fimmu.2020.01405

13922 Kim H, Ishibashi K, Iijima M, Kuroda S, Nakamura C. Influence of Nivolumab for Intercellular Adhesion Force between a T Cell and a Cancer Cell Evaluated by AFM Force Spectroscopy Sensors (Basel) 2020 20(19):5723 PubMed ID: 33050090 DOI: 10.3390/s20195723

14793 Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer Clin Cancer Res 2020 26(9):2244-2256 PubMed ID: 31953310 DOI: 10.1158/1078-0432.CCR-19-2321

14832 Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y. Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines Arch Virol 2020 165(1):207-214 PubMed ID: 31776677 DOI: 10.1007/s00705-019-04474-9

14834 Saito R, Miki Y, Abe T, Miyauchi E, Abe J, Nanamiya R, Inoue C, Sato I, Sasano H. 11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma Br J Cancer 2020 123(1):61-71 PubMed ID: 32336752 DOI: 10.1038/s41416-020-0837-3

17870 Yamaguchi T, Hayashi M, Ida L, Yamamoto M, Lu C, Kajino T, Cheng J, Nakatochi M, Isomura H, Yamazaki M, Suzuki M, Fujimoto T, Takahashi T. ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma Oncogene 2019 38(26):5142-5157 PubMed ID: 30894682 DOI: 10.1038/s41388-019-0785-7

11336 Kosibaty Z, Murata Y, Minami Y, Dai T, Kano J, Matsuoka R, Nakano N, Noguchi M. Cytoplasmic expression of epithelial cell transforming sequence 2 in lung adenocarcinoma and its implications for malignant progression. Lab. Invest. 2019 PubMed ID: 30542068 DOI: 10.1038/s41374-018-0142-4

11372 Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR. Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Rep 2019 PubMed ID: 30625329 DOI: 10.1016/j.celrep.2018.12.043

11384 Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun 2019 PubMed ID: 30651547 DOI: 10.1038/s41467-018-08074-0

11421 Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J. Cell. Mol. Med. 2019 PubMed ID: 30734495 DOI: 10.1111/jcmm.14205

11453 Kobayashi M, Saito R, Miki Y, Nanamiya R, Inoue C, Abe J, Sato I, Okada Y, Sasano H. The correlation of p22phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma. Oncotarget 2019 PubMed ID: 30800222 DOI: 10.18632/oncotarget.26637

11461 Imabayashi T, Uchino J, Osoreda H, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K. Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. Cancers (Basel) 2019 PubMed ID: 30818860 DOI: 10.3390/cancers11030282

4870 Udagawa H#1, Hasako S#2, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi S. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res 2019 17(11):2233-2243 PubMed ID: 31467113 DOI: 10.1158/1541-7786.MCR-19-0419

11746 Mizutani K, Guo X, Shioya A, Zhang J, Zheng J, Kurose N, Ishibashi H, Motono N, Uramoto H, Yamada S. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma. Int J Med Sci 2019 PubMed ID: 31588184 DOI: 10.7150/ijms.36071

11808 Sanomachi T, Suzuki S, Togashi K, Seino S, Yoshioka T, Kitanaka C, Okada M, Yamamoto M. Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. Anticancer Res. 2019 PubMed ID: 31519584 DOI: 10.21873/anticanres.13667

11848 Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M. Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. Cancers (Basel) 2019 PubMed ID: 31614999 DOI: 10.3390/cancers11101550

6892 Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer. Oncol Rep 2019 42(2):839-848 PubMed ID: 31173242 DOI: 10.3892/or.2019.7185

12553 Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, Chen T, Yang J, Jing M, Chen F, Wang C, Sun H, Huang Y. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis Int J Oncol 2019 54(1):370-380 PubMed ID: 30431083 DOI: 10.3892/ijo.2018.4626

14275 Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer Clin Cancer Res 2019 25(4):1248-1260 PubMed ID: 30352902 DOI: 10.1158/1078-0432.CCR-18-1640

14474 Mizuta S, Tagod MSO, Iwasaki M, Nakamura Y, Senju H, Mukae H, Morita CT, Tanaka Y. Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates ChemMedChem 2019 14(4):462-468 PubMed ID: 30637982 DOI: 10.1002/cmdc.201800764

14810 Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, Soh J, Tomida S, Toyooka S. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells Mol Cancer Res 2019 17(2):499-507 PubMed ID: 30463991 DOI: 10.1158/1541-7786.MCR-18-0628

10633 Asaka S, Yoshizawa A, Nakata R, Negishi T, Yamamoto H, Shiina T, Shigeto S, Matsuda K, Kobayashi Y, Honda T. Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens. Oncol Lett 2018 15:1469-1474 PubMed ID: 29399190 DOI: 10.3892/ol.2017.7464

10679 Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F. Capture of mesothelioma cells with 'universal' CTC-chip. Oncol Lett 2018 15:2635-2640 PubMed ID: 29434985 DOI: 10.3892/ol.2017.7619

10706 Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K. High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. Oncol Lett 2018 15:3061-3067 PubMed ID: 29435038 DOI: 10.3892/ol.2017.7671

10721 Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S. Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. Oncogenesis 2018 7:11 PubMed ID: 29362358 DOI: 10.1038/s41389-017-0017-3

10768 Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y. Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. Sci Rep 2018 8:3482 PubMed ID: 29472726 DOI: 10.1038/s41598-018-21161-y

10784 Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, Tanaka Y, Mukae H. Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy. Int. J. Biol. Sci. 2018 14:331-340 PubMed ID: 29559850 DOI: 10.7150/ijbs.22809

10785 Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. Carcinogenesis 2018 39:719-727 PubMed ID: 29546323 DOI: 10.1093/carcin/bgy044

11038 Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S, Yamada-Okabe H, Okada Y, Sasano H. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting Int J Mol Sci 2018 19. pii: E609 PubMed ID: 29463039 DOI: 10.3390/ijms19020609

11201 Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J. Exp. Clin. Cancer Res. 2018 PubMed ID: 30189871 DOI: 10.1186/s13046-018-0894-0

4141 Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C. Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells. Oncotarget 2018 PubMed ID: 30220973 DOI: 10.18632/oncotarget.25994

4320 Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, Iwai Y. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol. Lett. 2018 PubMed ID: 29366663 DOI: 10.1016/j.imlet.2018.01.007

4321 Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y. Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer. Oncotarget 2018 PubMed ID: 30680067 DOI: 10.18632/oncotarget.26494

14901 Enjoji S, Yabe R, Tsuji S, Yoshimura K, Kawasaki H, Sakurai M, Sakai Y, Takenouchi H, Yoshino S, Hazama S, Nagano H, Oshima H, Oshima M, Vitek MP, Matsuura T, Hippo Y, Usui T, Ohama T, Sato K. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis Mol Cancer Res 2018 16(3):554-563 PubMed ID: 29330298 DOI: 10.1158/1541-7786.MCR-17-0393

15838 Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations Mol Cancer Ther 2018 17(8):1648-1658 PubMed ID: 29748209 DOI: 10.1158/1535-7163.MCT-17-1206

15842 Zhou P, Chen G, Gao M, Wu J. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC Bioorg Med Chem 2018 26(23-24):6135-6145 PubMed ID: 30442506 DOI: 10.1016/j.bmc.2018.10.018

15843 Saito Y, Moriya S, Kazama H, Hirasawa K, Miyahara K, Kokuba H, Hino H, Kikuchi H, Takano N, Hiramoto M, Tsukahara K, Miyazawa K. Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis Int J Oncol 2018 1165-1177 PubMed ID: 29484439 DOI: 10.3892/ijo.2018.4282

10132 Liu Z, Yanagisawa K, Griesing S, Iwai M, Kano K, Hotta N, Kajino T, Suzuki M, Takahashi T. TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas. Oncogene 2017 36:3740-3748 PubMed ID: 28192407 DOI: 10.1038/onc.2016.524

10280 Seike M, Kim CH, Zou F, Noro R, Chiba M, Ishikawa A, Κunugi S, Kubota K, Gemma A. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Oncol. Rep. 2017 37:3261-3269 PubMed ID: 28440492 DOI: 10.3892/or.2017.5594

10317 Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, Takiguchi Y. Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. Oncol Lett 2017 14:944-950 PubMed ID: 28693256 DOI: 10.3892/ol.2017.6188

10530 Niessen S, Dix MM, Barbas S, Potter ZE, Lu S, Brodsky O, Planken S, Behenna D, Almaden C, Gajiwala KS, Ryan K, Ferre R, Lazear MR, Hayward MM, Kath JC, Cravatt BF. Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors. Cell Chem Biol 2017 24:1388-1400.e7 PubMed ID: 28965727 DOI: 10.1016/j.chembiol.2017.08.017

13708 Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, Suzuki M, Takahashi T. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells Cancer Sci 2017 108(7):1394-1404 PubMed ID: 28474808 DOI: 10.1111/cas.13271

14197 Planken S, Behenna DC, Nair SK, Johnson TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H, Cho-Schultz S, Dalvie D, Deal JG, Dinh DM, Edwards MP, Ferre RA, Gajiwala KS, Hemkens M, Kania RS, Kath JC, Matthews J, Murray BW, Niessen S, Orr ST, Pairish M, Sach NW, Shen H, Shi M, Solowiej J, Tran K, Tseng E, Vicini P, Wang Y, Weinrich SL, Zhou R, Zientek M, Liu L, Luo Y, Xin S, Zhang C, Lafontaine J. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR J Med Chem 2017 60(7):3002-3019 PubMed ID: 28287730 DOI: 10.1021/acs.jmedchem.6b01894

14432 Sato T, Shiba-Ishii A, Kim Y, Dai T, Husni RE, Hong J, Kano J, Sakashita S, Iijima T, Noguchi M. miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma Cancer Sci 2017 108(3):536-542 PubMed ID: 28012229 DOI: 10.1111/cas.13148

14449 Asaka S, Yoshizawa A, Matsuda K, Yamaguchi A, Yamamoto H, Shiina T, Nakata R, Ogawa K, Zhang M, Honda T. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens Oncol Rep 2017 37(2):1020-1026 PubMed ID: 27922678 DOI: 10.3892/or.2016.5287

14627 Chikaishi Y, Yoneda K, Ohnaga T, Tanaka F. EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip' Oncol Rep 2017 37(1):77-82 PubMed ID: 27840987 DOI: 10.3892/or.2016.5235

14680 Togo S, Katagiri N, Namba Y, Tulafu M, Nagahama K, Kadoya K, Takamochi K, Oh S, Suzuki K, Sakurai F, Mizuguchi H, Urata Y, Takahashi K. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients Oncotarget 2017 8(21):34884-34895 PubMed ID: 28432274 DOI: 10.18632/oncotarget.16818

14945 Togayachi A, Iwaki J, Kaji H, Matsuzaki H, Kuno A, Hirao Y, Nomura M, Noguchi M, Ikehara Y, Narimatsu H. Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma. J Proteome Res 2017 16:4495-4505 PubMed ID: 28949141 DOI: 10.1021/acs.jproteome.7b00484

15850 Inoue Y, Shiihara J, Miyazawa H, Ohta H, Higo M, Nagai Y, Kobayashi K, Saijo Y, Tsuchida M, Nakayama M, Hagiwara K. A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer PLoS One 2017 12(4):e0176525 PubMed ID: 28448556 DOI: 10.1371/journal.pone.0176525

7069 Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 2016 534:402-6 PubMed ID: 27281199 DOI: 10.1038/nature18294

9511 Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, Hotta N, Shimada Y, Isomura H, Suzuki M, Fujimoto T, Takahashi T. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun 2016 7:10060 PubMed ID: 26725982 DOI: 10.1038/ncomms10060

9598 Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int. J. Oncol. 2016 48:1825-36 PubMed ID: 26984042 DOI: 10.3892/ijo.2016.3419

9731 Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O. Establishment of anti-mesothelioma monoclonal antibodies. BMC Res Notes 2016 9:324 PubMed ID: 27342200 DOI: 10.1186/s13104-016-2128-x

9884 Watarai H, Okada M, Kuramoto K, Takeda H, Sakaki H, Suzuki S, Seino S, Oizumi H, Sadahiro M, Kitanaka C. Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin. Anticancer Res. 2016 36:6083-6092 PubMed ID: 27793936 DOI: 10.21873/anticanres.11198

10010 Koh V, Kwan HY, Tan WL, Mah TL, Yong WP. Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells. BMC Genomics 2016 17:1029 PubMed ID: 28155658 DOI: 10.1186/s12864-016-3322-x

12883 Ida L, Yamaguchi T, Yanagisawa K, Kajino T, Shimada Y, Suzuki M, Takahashi T. Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma Cancer Sci 2016 107(2):155–161 PubMed ID: 26661061 DOI: 10.1111/cas.12858

13967 Lee Y, Choi YR, Kim KY, Shin DH. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation Oncotarget 2016 7(28):43315-43323 PubMed ID: 27270313 DOI: 10.18632/oncotarget.9703

14033 Iyama S, Ono M, Kawai-Nakahara H, Husni RE, Dai T, Shiozawa T, Sakata A, Kohrogi H, Noguchi M. Drebrin: A new oncofetal biomarker associated with prognosis of lung adenocarcinoma Lung Cancer 2016 102:74-81 PubMed ID: 27987592 DOI: 10.1016/j.lungcan.2016.10.013

14179 Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KK, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr ST, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants J Med Chem 2016 59(5):2005-24 PubMed ID: 26756222 DOI: 10.1021/acs.jmedchem.5b01633

7103 Greig MJ, Niessen S, Weinrich SL, Feng JL, Shi M, Johnson TO. Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry. Int J Cell Biol 2015 2015:798936 PubMed ID: 26689952 DOI: 10.1155/2015/798936

7346 Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, Hsu TL, Yang PC, Wong CH. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc. Natl. Acad. Sci. U.S.A. 2015 112:6955-60 PubMed ID: 25971727 DOI: 10.1073/pnas.1507329112

7402 Sugita S, Ito K, Yamashiro Y, Moriya S, Che XF, Yokoyama T, Hiramoto M, Miyazawa K. EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. Biochem. Biophys. Res. Commun. 2015 461:28-34 PubMed ID: 25858318 DOI: 10.1016/j.bbrc.2015.03.162

7498 Sakamoto T, Kodani M, Takata M, Chikumi H, Nakamoto M, Nishii-Ito S, Ueda Y, Izumi H, Makino H, Touge H, Takeda K, Yamasaki A, Yanai M, Tanaka N, Igishi T, Shimizu E. A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer. Int. J. Oncol. 2015 46:1473-80 PubMed ID: 25651992 DOI: 10.3892/ijo.2015.2875

7523 Elza C. de Bruin, Ming Jiang, Michael Howell, Julian Downward Genome-Wide siRNA Screen for Anti-Cancer Drug Resistance in Adherent Cell Lines. Bio-protocol 2015 5:e1474 DOI: 10.21769/BioProtoc.1474

15025 Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment Genome Biol 2015 16(1):66 PubMed ID: 25887790 DOI: 10.1186/s13059-015-0636-y

15223 Takahashi A, Ishii G, Ner Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth Oncotarget 2015 6(11):9531-41 PubMed ID: 25909164 DOI: 10.18632/oncotarget.3371

15458 Izumi H, Touge H, Igishi T, Makino H, Nishii-Ito S, Takata M, Nakazaki H, Ueda Y, Matsumoto S, Kodani M, Kurai J, Takeda K, Sakamoto T, Yanai M, Tanaka N, Nirodi CS, Shimizu E. Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies Int J Oncol 2015 46(3):989-98 PubMed ID: 25573239 DOI: 10.3892/ijo.2015.2815

15825 Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment Cancer Sci 2014 105(10):1236-44 PubMed ID: 25154680 DOI: 10.1111/cas.12503

15832 Nozaki K, Kagamu H, Shoji S, Igarashi N, Ohtsubo A, Okajima M, Miura S, Watanabe S, Yoshizawa H, Narita I. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations PLoS One 2014 9(10):e111019 PubMed ID: 25343452 DOI: 10.1371/journal.pone.0111019

16301 Xue R, Han N, Sakurai H, Saiki I, Ye C, Yin J. Cytotoxic cardiac glycosides from the roots of Streptocaulon juventas Planta Med 2013 79(2):157-62 PubMed ID: 23225367 DOI: 10.1055/s-0032-1328021

15834 Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity Cancer Biol Ther 2012 13(6):369-78. PubMed ID: 22313637 DOI: 10.4161/cbt.19238

15715 Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma PLoS One 2011 6(9):e25301 PubMed ID: 21966491 DOI: 10.1371/journal.pone.0025301

15844 Hotta K, Tabata M, Kiura K, Kozuki T, Hisamoto A, Katayama H, Takigawa N, Fujimoto N, Fujiwara K, Ueoka H, Tanimoto M. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation Oncol Rep 2007 17(2):313-7 PubMed ID: 17203166